Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10675561 | 1.00 | SLC6A2 (0.69) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| Cadaverine Tartrate SCHEMBL30658440 | 0.87 | ADRA2B (0.54) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| Cadaverine Tartrate SCHEMBL20702014 | 0.87 | ADRA2B (0.54) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| SCHEMBL20237216 | 0.82 | SLC6A2 (0.50) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| Benzphetamine SCHEMBL19285634 | 0.82 | ADRA2B (1.00) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| SCHEMBL12658318 | 0.82 | SLC6A2 (0.50) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| Benzphetamine SCHEMBL678807 | 0.82 | ADRA2B (1.00) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| Benzphetamine SCHEMBL49120 | 0.82 | ADRA2B (1.00) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| SCHEMBL15003030 | 0.82 | ADRA2B (0.71) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 | |
| Benzphetamine SCHEMBL260091 | 0.80 | ADRA2B (0.96) | SLC6A2ADRA2BADRA2CADRA1AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | claimed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2021-12-23 | — | — | US | disclosed |
| US-11130746-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200255404-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10696654-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| EP-3408265-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| WO-2017129829-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696654-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885 |
| US-11753398-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885 |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885 |
| US-11130746-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885 |
| US-20200255404-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885 |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | SLC6A2 317/4885ADRA2B 501/4885ADRA2C 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.